The GLP-1/GIP dual receptor agonist tirzepatide, like most GLP-1 receptor agonists, is administered subcutaneously. The application takes place once a week. Like Glutide, Tirzepatid can cause nausea, Vomitdiarrhea, decreased appetite, constipation, upper abdominal discomfort and abdominal pain.
Type 2 diabetes: tirzepatide approved in the US
:watermark(assets.rndtech.de/rnd/watermark-plus.svg,50,50,0)/cloudfront-eu-central-1.images.arcpublishing.com/madsack/XQXR234UYNCWNLNI2UG2ZAAPFY.gif)
/cloudfront-eu-central-1.images.arcpublishing.com/madsack/OS7CY477LJAEBFNK2D5QVCP4R4.jpeg)
